Skip to main content
Premium Trial:

Request an Annual Quote

Tekmira, Collaborators Demonstrate HCV Knockdown In Vivo with RNAi

Premium

Tekmira Pharmaceuticals this week announced that, along with collaborators at SomaGenics and Roche, it has shown in vivo efficacy of an RNAi molecule against hepatitis C virus.

“In this work, short hairpin RNAs that target a conserved region of the HCV genome were delivered systemically using Tekmira's lipid nanoparticle technology, resulting in a significant and durable reduction in viral load in HCV-infected animals," Tekmira President and CEO Mark Murray said in a statement.

Specifically, shRNAs were taken up by liver cells in a chimeric mouse model, Tekmira said. Additionally, a single intravenous dose of the agent was sufficient to trigger “significant HCV reduction.”

The biggest effect was achieved with a cocktail of two shRNAs targeting two different sites on the HCV genome, with additional “potent and durable” inhibition after a second dose, the company added.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.